Comparative Pharmacology
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXIPRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PAPA DEINE 4 versus ROXIPRIN.
PAPA-DEINE #4 vs ROXIPRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetaminophen: centrally acting analgesic and antipyretic, inhibits cyclooxygenase (COX) enzymes, primarily in the CNS, reducing prostaglandin synthesis. Codeine: opioid agonist, binds to mu-opioid receptors in the CNS, altering pain perception and emotional response to pain.
Roxiprin is a combination analgesic containing rofecoxib (a COX-2 selective NSAID) and paracetamol (acetaminophen, a centrally acting analgesic/antipyretic). Rofecoxib inhibits prostaglandin synthesis by selectively blocking cyclooxygenase-2, reducing pain and inflammation. Paracetamol inhibits cyclooxygenase in the central nervous system and modulates descending serotonergic pathways, providing analgesia and antipyresis.
1-2 tablets orally every 4-6 hours as needed for pain, not to exceed 8 tablets per day.
500 mg orally every 6 to 8 hours as needed for pain or fever; maximum 2000 mg per day.
None Documented
None Documented
2-4 hours. In hepatic or renal impairment, half-life may increase to 4-6 hours, requiring dose adjustment.
2.5 hours (prolonged to 4-6 hours in hepatic impairment; no significant change in renal impairment)
Renal: ~90% (70% as glucuronide conjugates, 10% as morphine, 10% as normorphine). Biliary/fecal: ~10%.
Renal (70% as unchanged drug, 20% as glucuronide conjugate); biliary/fecal (10%)
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination